摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(2'-deoxy-β-D-erythro-pentofuranosyl)-1H-imidazo<4,5-c>pyridine | 98858-23-2

中文名称
——
中文别名
——
英文名称
1-(2'-deoxy-β-D-erythro-pentofuranosyl)-1H-imidazo<4,5-c>pyridine
英文别名
1-(2'-deoxy-β-D-erythro-pentofuranosyl)-1H-imidazo[4,5-c]pyridine;(2R,3S,5R)-2-(hydroxymethyl)-5-imidazo[4,5-c]pyridin-1-yloxolan-3-ol
1-(2'-deoxy-β-D-erythro-pentofuranosyl)-1H-imidazo<4,5-c>pyridine化学式
CAS
98858-23-2
化学式
C11H13N3O3
mdl
——
分子量
235.243
InChiKey
ICRFUVHKFMKEIV-HBNTYKKESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.3
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    80.4
  • 氢给体数:
    2
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    参考文献:
    名称:
    3-Deaza-2'-脱氧腺苷和3-Deaza-2',3'-二脱氧腺苷的合成:4-氯咪唑并[4,5- c ]吡啶基阴离子的糖基化
    摘要:
    3-deazapurine2'-deoxy-β-D-核糖核苷和2',3'-deideoxy-D-核糖核苷的聚合合成,包括3-deaza-2'-deoxyadenosine(1a)和3-deaza-2',描述了3'-二脱氧腺苷(1b)。使源自5的4-氯-1 H-咪唑并[4,5-c]吡啶基阴离子与2'-脱氧卤代糖6或2',3'-二脱氧卤代糖10反应,产生两个区域异构(N 1和N 3)糖基化产品。将它们脱保护并转化为4-取代的咪唑并[4,5-c]吡啶2′-脱氧-β-D-核糖核苷和2′,3′-二脱氧-D-核糖核苷。化合物1a和1b被证明比母体嘌呤核苷对质子催化的N-糖基键水解更稳定,并且不被腺苷脱氨酶脱氨基。
    DOI:
    10.1002/hlca.19900730605
点击查看最新优质反应信息

文献信息

  • Synthesis of 2-Deoxy-β-D-ribonucleosides and 2,3-Dideoxy-β-D-pentofuranosides on Immobilized Bacterial Cells
    作者:Ivan Votruba、Antonín Holý、Hana Dvořáková、Jaroslav Günter、Dana Hocková、Hubert Hřebabecký、Tomas Cihlar、Milena Masojídková
    DOI:10.1135/cccc19942303
    日期:——

    Alginate gel-entrapped cells of auxotrophic thymine-dependent strain of E. coli catalyze the transfer of 2-deoxy-D-ribofuranosyl moiety of 2'-deoxyuridine to purine and pyrimidine bases as well as their aza and deaza analogs. All experiments invariably gave β-anomers; in most cases, the reaction was regiospecific, affording N9-isomers in the purine and N1-isomers in the pyrimidine series. Also a 2,3-dideoxynucleoside can serve as donor of the glycosyl moiety. The acceptor activity of purine bases depends only little on substitution, the only condition being the presence of N7-nitrogen atom. On the other hand, in the pyrimidine series the activity is limited to only a narrow choice of mostly short 5-alkyl and 5-halogeno uracil derivatives. Heterocyclic bases containing amino groups are deaminated; this can be avoided by conversion of the base to the corresponding N-dimethylaminomethylene derivative which is then ammonolyzed. The method was verified by isolation of 9-(2-deoxy-β-D-ribofuranosyl) derivatives of adenine, guanine, 2-chloroadenine, 6-methylpurine, 8-azaadenine, 8-azaguanine, 1-deazaadenine, 3-deazaadenine, 1-(2-deoxy-β-D-ribofuranosyl) derivatives of 5-ethyluracil, 5-fluorouracil, and 9-(2,3-dideoxy-β-D-pentofuranosyl)hypoxanthine, 9-(2,3-dideoxy-β-D-pentofuranosyl)-6-methylpurine, and other nucleosides.

    藻酸盐凝胶包埋的辅助胸腺嘧啶依赖菌株大肠杆菌细胞催化2'-脱氧尿嘧啶的2-脱氧-D-核糖呋喃基团转移到嘌呤和嘧啶碱基以及它们的氮杂和去氮类似物。所有实验都不可避免地产生β-异构体;在大多数情况下,反应是区域特异性的,产生嘌呤中的N9-异构体和嘧啶系列中的N1-异构体。此外,2,3-二脱氧核苷酸可以作为糖基团的供体。嘌呤碱基的受体活性仅在取代上有少许影响,唯一的条件是存在N7-氮原子。另一方面,在嘧啶系列中,活性仅限于大多数短链5-烷基和5-卤代尿嘧啶衍生物的狭窄选择。含氨基的杂环碱基会发生脱氨作用;可以通过将碱基转化为相应的N-二甲氨基甲烯基衍生物来避免这种情况,然后进行氨解作用。该方法通过分离腺嘌呤、鸟嘌呤、2-氯腺嘌呤、6-甲基嘌呤、8-氮杂腺嘌呤、8-氮杂鸟嘌呤、1-去氮腺嘌呤、3-去氮腺嘌呤的9-(2-脱氧-β-D-核糖呋喃基)衍生物,5-乙基尿嘧啶、5-氟尿嘧啶的1-(2-脱氧-β-D-核糖呋喃基)衍生物,以及9-(2,3-二脱氧-β-D-戊呋喃基)缺氧嘌呤、9-(2,3-二脱氧-β-D-戊呋喃基)-6-甲基嘌呤和其他核苷酸的验证。
  • SEELA, FRANK;ROSEMEYER, HELMUT;FISCHER, SABINE, HELV. CHIM. ACTA, 73,(1990) N, C. 1602-1611
    作者:SEELA, FRANK、ROSEMEYER, HELMUT、FISCHER, SABINE
    DOI:——
    日期:——
  • Synthesis of 3-Deaza-2?-deoxyadenosine and 3-Deaza-2?,3?-dideoxyadenosine: Glycosylation of the 4-Chloroimidazo[4,5-c]pyridinyl Anion
    作者:Frank Seela、Helmut Rosemeyer、Sabine Fischer
    DOI:10.1002/hlca.19900730605
    日期:1990.9.19
    3-deaza-2′,3′-dideoxyadenosine (1b) is described. The 4-chloro-lH-imidazo[4,5-c]pyridinyl anion derived from 5 was reacted with either 2′-deoxyhalogenose 6 or 2′,3′-dideoxyhalogenose 10 yielding two regioisomeric (N1 and N3) glycosylation products. They were deprotected and converted into 4-substituted imidazo[4,5-c]pyridine 2′-deoxy-β-D-ribonucleosides and 2′,3′-dideoxy-D-ribonucleosides. Compounds
    3-deazapurine2'-deoxy-β-D-核糖核苷和2',3'-deideoxy-D-核糖核苷的聚合合成,包括3-deaza-2'-deoxyadenosine(1a)和3-deaza-2',描述了3'-二脱氧腺苷(1b)。使源自5的4-氯-1 H-咪唑并[4,5-c]吡啶基阴离子与2'-脱氧卤代糖6或2',3'-二脱氧卤代糖10反应,产生两个区域异构(N 1和N 3)糖基化产品。将它们脱保护并转化为4-取代的咪唑并[4,5-c]吡啶2′-脱氧-β-D-核糖核苷和2′,3′-二脱氧-D-核糖核苷。化合物1a和1b被证明比母体嘌呤核苷对质子催化的N-糖基键水解更稳定,并且不被腺苷脱氨酶脱氨基。
查看更多

同类化合物

4-氨基-1-(2’,3’,5’-三-O-叔-丁基二甲基硅烷基-beta-D-呋喃核糖基)-咪唑并[4,5-a]吡啶 3-脱氮腺苷 3-去氮杂鸟苷酸 3-去氮杂鸟苷三磷酸酯 3-去氮杂鸟苷 1-(2-脱氧-beta-D-赤式-呋喃戊糖基)-1H-咪唑并[4,5-c]吡啶-4-胺 1-(2,3,5-三-O-乙酰基-beta-D-呋喃核糖基)-4,6-二氯咪唑并[4,5-c]吡啶 5'-O-(N-L-seryl)sulfamoyl-3-deaza-adenosine 5'-O-(N-glycyl)sulfamoyl-3-deaza-adenosine 5'-O-(N-L-isoleucyl)sulfamoyl-3-deaza-adenosine 2-Fluoro-3-deaza-adenosine 4-(pyridin-3-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 4-(pyrrol-3-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 4-(pyrrol-2-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 4-(furan-2-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 1-(β-D-ribofuranosyl)-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridine 4-cyclopropyl-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 4-methyl-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 1-(β-D-ribofuranosyl)-4-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridine Adenosine, 3-deaza- (2R,3S,5R)-5-(4-Dimethylamino-imidazo[4,5-c]pyridin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-ol (2R,3S,5R)-2-Hydroxymethyl-5-(4-mercapto-imidazo[4,5-c]pyridin-1-yl)-tetrahydro-furan-3-ol 4-chloro-7-fluoro-1-(2'-C-methyl-β-D-ribofuranosyl)-imidazo[4,5-c]pyridine 4-ethyl-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine (2R,3S,5R)-5-(4-Benzylamino-imidazo[4,5-c]pyridin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-ol 4-(Methylsulfanyl)-1-pentofuranosyl-1H-imidazo[4,5-c]pyridine 4,7-difluoro-1-(2,3,5-tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)-imidazo[4,5-c]pyridine 6-Chloro-n,n-dimethyl-1-pentofuranosyl-1h-imidazo[4,5-c]pyridin-4-amine 2-(6-Chloro-4-methoxyimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 2-(4-Benzylsulfanyl-6-chloroimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 2-(6-Chloro-4-methylsulfanylimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol N-[4-bromo-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazo[4,5-c]pyridin-6-yl]acetamide 5,6-Diamino-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazo[4,5-c]pyridin-4-one 1-amino-3-deazaguanosine 3-deazainosine 6-chloro-4-(cyclohexylamino)-1-(3-deoxy-β-D-ribofuranosyl)-1H-imidazo<4,5-c>pyridine [(2R,3R,4R,5R)-3,4-dibenzoyloxy-5-(4,6-dichloroimidazo[4,5-c]pyridin-1-yl)-4-methyloxolan-2-yl]methyl benzoate 4-amino-6-chloro-1-(3-deoxy-β-D-ribofuranosyl)-1H-imidazo<4,5-c>pyridine 4-amino-1-(2-deoxy-b-d-ribofuranosyl)-7-(1-naphthylethynyl)-imidazo[4,5-c]pyridine 3-Deazaguanosine 3',5'-cyclic phosphate 4-chloro-7-fluoro-1-(β-D-ribofuranosyl)imidazo[4,5-c]pyridine (2R,3S,5R)-5-(4-Benzylsulfanyl-imidazo[4,5-c]pyridin-1-yl)-2-hydroxymethyl-tetrahydro-furan-3-ol 4-(1H-pyrazol-5-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine 2-bromo-5-methyl-1-(2,3,5-tri-O-t-butyldimethyl-silyl-β-D-ribofuranosyl)imidazo[4,5-c]pyridin-4(5H)-one 4-amino-6-fluoro-1-(2,3,5-tri-O-benzyl-β-D-arabinofuranosyl)imidazo[4,5-c]pyridine 4-amino-6-fluoro-1-(2,3,5-tri-O-benzyl-α-D-arabinofuranosyl)imidazo[4,5-c]pyridine 4-chloro-1-(2',3'-dideoxy-α-D-glycero-pentofuranosyl)-1H-imidazo<4,5-c>pyridine 4-chloro-1-(2',3'-dideoxy-5'-O-<(1'',1 ''-dimethylethyl)dimethylsilyl>-β-D-glycero-pentofuranosyl)-1H-imidazo<4,5-c>pyridine 4-chloro-1-(2',3'-dideoxy-5'-O-<(1'',1 ''-dimethylethyl)dimethylsilyl>-α-D-glycero-pentofuranosyl)-1H-imidazo<4,5-c>pyridine 4-(furan-3-yl)-1-(β-D-ribofuranosyl)-1H-imidazo[4,5-c]pyridine